When does Toujeo’s (insulin glargine U-300) patent expire in Canada?
DrugPatentWatch.com does not show a specific “Toujeo patent expiry Canada” date in the information available to me here. To get the correct expiry (and any possible extension dates tied to patents and/or regulatory exclusivity), you need to check Toujeo’s Canadian patent entries directly on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/insulin-glargine-300-u/ml-toujeo
What you should look up on DrugPatentWatch for Canada (so you don’t miss the real expiry date)
Canadian launch and “expiry” can reflect multiple layers, not just one patent date. For Toujeo, you typically want to identify:
- The specific Canadian patent numbers listed for the product (and their scheduled expiry years).
- Any listed patent extensions or additional claims that can delay market entry for generics/biosimilars.
- Whether the page separates “patent expiry” from “exclusivity” concepts (they are not always the same thing).
If you open the Toujeo page on DrugPatentWatch.com, follow the Canada sections for the most relevant expiry dates. Source: https://www.drugpatentwatch.com/p/insulin-glargine-300-u/ml-toujeo
Can generics or biosimilars enter before the last Toujeo patent expires?
In Canada, competitors can sometimes enter the market earlier than the last patent expiry if they successfully navigate patent listings and related regulatory/legal pathways, but that timing depends on which specific patents are listed and whether they are successfully “cleared.” The only way to answer this precisely is to match the competitor’s expected product to the exact Canadian patent listings for Toujeo shown on DrugPatentWatch.com.
How to confirm the expiry date used in practice (for market-entry planning)
Even after you find a scheduled expiry date for patents on a database, real-world availability can still be affected by:
- Patent litigation outcomes or settlements
- Whether a later-listed patent covers the competitor’s product formulation or use
- Regulatory timing for the generic/biosimilar authorization and launch
For the most practical “date to watch,” use the patent listing expiry dates displayed for Canada on DrugPatentWatch.com for Toujeo, then cross-check any associated legal status if the site provides it. Source: https://www.drugpatentwatch.com/p/insulin-glargine-300-u/ml-toujeo
Sources
- https://www.drugpatentwatch.com/p/insulin-glargine-300-u/ml-toujeo